Follow us on Twitter
twitter icon@FreshPatents


Cholesterol patents

      

This page is updated frequently with new Cholesterol-related patent applications.




 Disease management systems comprising dietary supplements patent thumbnailDisease management systems comprising dietary supplements
Described herein are integrated programs and systems that manage or treat chronic conditions such as elevated cholesterol or elevated blood pressure and other health conditions. The integrated system may include a combination of: a dietary supplement; behavior change messaging through packaging (including use of unit dose packaging) and/or package inserts; video content available through the web or mobile means; interactive discussions with healthcare providers; and an app or website that supports behavior change as well as tracks ongoing compliance to the dietary supplement and behavior change as well as physiologic endpoints.

 Grating, display device, and manufacturing  grating patent thumbnailGrating, display device, and manufacturing grating
A grating, a manufacturing method of grating and a display device are disclosed. The grating comprises a first substrate (21) and a second substrate (22) which are oppositely disposed; a first transparent electrode (23) which has a grating structure and is disposed on a side of the first substrate (21) facing towards the second substrate (22); a second transparent electrode (24) which is disposed on a side of the second substrate (22) facing towards the first substrate (21) and is disposed to be opposite to the first transparent electrode (23); and a polymer layer (25) which is disposed between the first transparent electrode (23) and the second transparent electrode (24), the polymer layer containing therein nano-sized material converting electromagnetic energy into heat energy and liquid crystalline elastomers.
Beijing Boe Optoelectronics Technology Co., Ltd.


 Method and system for treating non-alcoholic fatty liver disease patent thumbnailMethod and system for treating non-alcoholic fatty liver disease
A method and system for treating non-alcoholic fatty liver disease (nafld) involves the modulation of the gut microbial of a person suffering from nafld, and in particular the provision of a probiotic therapy configured to reduce liver aminotransferases, total-cholesterol, tnf-α and to improve insulin resistance in nafld patients.. .

 Compositions and methods for making alpha-(1,2)-branched alpha-(1,6)  oligodextrans patent thumbnailCompositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans
Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kda and 70 kda, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity.
Tate & Lyle Ingredients France Sas


 Ldlr variants and their use in compositions for reducing cholesterol levels patent thumbnailLdlr variants and their use in compositions for reducing cholesterol levels
A recombinant vector having an expression cassette is provided which comprises a modified human low density lipoprotein receptor (hldlr) gene is provided, wherein said hldlr gene encodes a modified hldlr comprising (a) one or more of the following amino acid substitutions: l318h, n295d, h306d, v307d, n309a, d310n, l318h, and/or l318d; or (b) an amino acid substitution of any of (a) in combination with one or more of the following amino acid substitutions: k796, k809r and/or c818a. Also provided are pharmaceutical compositions containing this vector and uses therefor in lowering cholesterol and/or treating familial hypercholesterolemia..
The Trustees Of The University Of Pennsylvania


 In vitro model for neuronal death patent thumbnailIn vitro model for neuronal death
This invention demonstrates the formation of a novel polarized membrane lipid raft signaling module in neurons, in response to several diverse neurotoxic stimuli. This polarization occurs well before neurons commit to die, and is an early mechanism in death signaling.

 Administering antisense oligonucleotides complementary to human apolipoprotein b patent thumbnailAdministering antisense oligonucleotides complementary to human apolipoprotein b
Methods for long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated ldl-cholesterol and elevated apob are provided.. .
Kastle Therapeutics, Llc


 Anti-pcsk9 antibodies with ph-dependent binding characteristics patent thumbnailAnti-pcsk9 antibodies with ph-dependent binding characteristics
An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hpcsk9) characterized by the ability to reduce serum ldl cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum hdl cholesterol and/or with little or no measurable effect on liver function, as determined by alt and ast measurements.. .
Regeneron Pharmaceuticals, Inc.


 Amphotericin b derivative with reduced toxicity patent thumbnailAmphotericin b derivative with reduced toxicity
Disclosed is a derivative of amphotericin b (amb), denoted c2′epiamb, with an improved therapeutic index over amphotericin b, pharmaceutical compositions comprising the amb derivative, methods of making the amb derivative and the pharmaceutical composition, and their use in methods of inhibiting growth of a yeast or fungus and treating a yeast or fungal infection. C2′epiamb is an epimer of the parent compound.
The Board Of Trustees Of The University Of Illinois


 Dry powder formulation of azole derivative for inhalation patent thumbnailDry powder formulation of azole derivative for inhalation
A spray dried-powder composition for inhalation comprising particles (x) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as sorbitol, mannitol and xylitol; a monosaccharides such as glucose and arabinose; disaccharide such as lactose, maltose, saccharose and dextrose; cholesterol, and any mixture thereof, wherein the composition provides a dissolution rate of said azole derivative of at least, 5% within 10 minutes, 10% within 20 minutes and 40% within 60 minutes when tested in the dissolution apparatus type 2 of the united states pharmacopoeia at 50 rotation per minute, 37° c. In 900 milliliters of an aqueous dissolution medium adjusted at ph 1.2 and containing 0.3% of sodium laurylsulfate..
Galephar Pharmaceutical Research, Inc.


Irinotecan hydrochloride composite phospholipid composition, preparation method and use thereof

An irinotecan hydrochloride composite phospholipid composition, preparation method and uses thereof in the preparation of drugs for treating tumors or drug resistant tumors. The composite phospholipid composition comprises irinotecan hydrochloride, composite phospholipid, cholesterol, long-circulating membrane material, surfactant and a buffer medium.
Shanghai Jingfeng Pharmaceutical Co., Ltd.

Method of correcting for oxygen effect

An electrochemical test sensor is adapted to measure glucose and correct for the oxygen effect in a fluid sample. The test sensor comprises a base, first and second working electrodes, and a counter electrode.
Ascensia Diabetes Care Holdings Ag

Liquid crystal composition, liquid crystal display device and its manufacturing method

The present disclosure provides a liquid crystal composition, a liquid crystal display device and its manufacturing method. The liquid crystal composition comprises a first composition and an ethylene-vinyl acetate copolymer at a ratio by mass of the first composition to the ethylene-vinyl acetate copolymer of 2:3 to 4:1, wherein the first composition comprises 15 to 40 parts by weight of a chiral cholesterol ester compound, 59 to 75 parts by weight of nematic phase liquid crystal, and 1 to 10 parts by weight of ferroferric oxide.
Beijing Boe Optoelectronics Technology Co., Ltd.

Antidiabetic tricyclic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Pharmaceutical composition for controlling blood lipids and body weight, and use thereof

The invention provides a traditional chinese medicine composition for the control of blood lipids and/or weight of body, which includes poria and paeoniae radix alba, etc. The traditional chinese medicine composition can be applied in reducing the total cholesterol level, triacylglycerol level, and low density lipoprotein cholesterol level in the body; increasing body high density lipoprotein cholesterol level, reducing uric acid level, and/or reducing symptoms of fatty liver.
Beijing Hebabiz Management Co., Ltd.

Drug combinations and uses

The present specification discloses compositions comprising a pharmaceutical composition to reduce or maintain ldl and/or cholesterol levels in an individual and a plurality of therapeutic compounds to increase or maintain hdl levels in an individual. The present specification also discloses a treatment protocol wherein a pharmaceutical composition is administered to an individual on a schedule wherein the pharmaceutical composition is provided for a period of time and then not provided to the individual and this treatment protocol is repeated for the term of the individual's treatment..
Biocopea Limited

Raw uncooked/unbaked dessert rolls

A method of preparation of raw, uncooked or unbaked dessert rolls is such that they are unbaked or uncooked in any conventional high temperature process exceeding 120 degrees fahrenheit. The method includes using ingredients free from all refined sugars, eggs, flour, gluten, cholesterol, high fructose corn syrup, hydrogenated oils, or any artificial preservatives.

Mrna therapy for phenylketonuria

The present invention provides, among other things, methods of treating phenylketonuria (pku), including administering to a subject in need of treatment a composition comprising an mrna encoding phenylalanine hydroxylase (pah) at an effective dose and an administration interval such that at least one symptom or feature of pku is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mrna is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more peg-modified lipids.
Shire Human Genetic Therapies, Inc.

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.

Composition comprising scirpusin a and scirpusin b and anti-obesity potential thereof

Disclosed are methods of managing hypercholesterolemia using a composition of matter comprising the ethyl acetate fraction of the extract of cyperus rotundus rhizomes standardized to contain 5% of total stilbenes.. .

Extracts of cyclanthera pedata and formulations and uses thereof

The invention provides a method for extracting active therapeutic components from plant materials of the cyclanthera pedata plant which comprises immersing said plant material containing active components and selected from the group consisting of fruits, flowers, leaves, stems, twigs, bark, wood, buds, seeds, roots, and pods in a solvent for a period of time of about 30 minutes to about 10 hours to achieve transfer of active components from the plant material to the solvent, separating the solvent containing active components from the plant material, and evaporating or distilling the solvent to produce a concentrated fraction containing active components. The invention further includes compositions and therapeutic formulations of such extracts to treat hypercholesterolemia and other high lipid related diseases..

Pharmaceutical composition based on a hepatoprotector and prebiotic, and administrating

The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelitiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced and toxic liver damage. The pharmaceutical composition is administered by mouth and contains a hepatoprotector and a prebiotic taken, as an active agent, in therapeutically effective doses.

Methods of determining efficacy of therapy for niemann-pick c disease and related disorders

A method for identifying and screening subjects for cholesterol storage or trafficking diseases using an oxysterol as a biomarker. More particularly, subjects are screened and can be identified as having niemann-pick c disease, the method comprising the steps quantifying the concentration of an oxysterol in a biological sample taken from the subject and comparing the concentration of the oxysterol of the subject to a reference value of the oxysterol derived from a non-affected subject population.
The United States Of America, National Institutes Of Health, As Represented By The Sec. Dept Hhs

Pcsk9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Embodiments provide swallowable devices, preparations and methods for delivering therapeutic agents (tas) within the gi tract such as antibodies (ap-antibodies) or other proteins which neutralize pcsk9 molecules. Many embodiments provide a swallowable device e.g., a capsule for delivering tas into the intestinal wall (iw).
Rani Therapeutics, Llc

Lactococcus lactis strains

New lactococcus lactis strains, nrrl b-50571 and nrrl b-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower ldl-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation..
Centro De Investigación En Alimentación Y Desarrollo, A.c. (ciad)

Lactococcus lactis strains

New lactococcus lactis strains, nrrl b-50571 and nrrl b-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower ldl-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation..
Centro De Investigación En Alimentacion Y Desarrollo, A.c. (ciad)

Serum cholesterol lowering edible product

The present invention relates to a serum ldl cholesterol lowering edible product containing plant sterol ester and/or plant stanol ester, and especially to a dietary supplement product.. .
Raisio Nutrition Ltd

Proliposomal testosterone formulations

Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with phamarceutically acceptable excipients to form pharmaceutical compositions.
Tesorx Pharma, Llc

Cell culture media

A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (atra) and vitamin c; zinc, magnesium, and copper; an agent that increases intracellular camp; epidermal growth factor (egf); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin d, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors.. .
The University Of Florida Research Foundation, Inc

Use of aromatic-cationic peptides to treat cholesterol-induced mitochondrial dysfunction

The present disclosure provides aromatic-cationic peptide compositions and methods of using the same. The methods comprise use of the peptides in inhibiting cholesterol-induced cytochrome c peroxidase activity, promoting reduction of cytochrome c, and inhibition of cardiolipin peroxidation to treat, prevent or ameliorate cholesterol-induced mitochondrial dysfunction..
Cornell University

Method of lowering cholesterol

The present invention relates to the diagnosis, risk assessment, prevention, and treatment of senile dementia of the alzheimer's type (sdat). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum.
Phenomenome Discoveries Inc.

Fat-based food products

The invention is in particular concerned with a food product comprising one or more fats or oils and a carotenoid compound. The products of the invention may be used in reducing elevated total cholesterol, triglycerides and inflammatory damage, as well as improving tissue microcirculation and tissue oxygenation..
Ip Science Limited

Novel low molecular weight cationic lipids for oligonucleotide delivery

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.
Sirna Therapeutics, Inc.

Derivatives of ergostatrien-3-beta-ol from antrodia camphorata and antiglycemic, antihyperlipidemic and decreasing hepatic fat use thereof

The present invention provides a method for treating diabetes, hyperlipidemia or hepatic total lipids by using ergostatrien-3β-ol and its derivatives, as well as a method for decreasing blood glucose and hba1c levels and reducing blood total cholesterol and triglyceride levels, whereas increasing blood hdl-c levels; and a method for decreasing hepatic total lipid and triacylglycerol levels; and increasing expression levels of membrane glucose transporter 4 (glut4) and phospho-akt in skeletal muscle tissue, and phospho-ampk in both skeletal muscle and liver tissue using ergostatrien-3β-ol and its derivatives.. .

Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
Vanderbilt University

Methods targeting mir-128 for regulating cholesterol/lipid metabolism

Methods for targeting microrna 128 (mir-128) for regulating cholesterol/lipid metabolism and insulin sensitivity.. .
The General Hospital Corporation

Nanoparticulate compositions for targeted delivery of acid labile, lipophilic prodrugs of cancer chemotherapeutics and their preparation

In one embodiment, the present application discloses synthetic ldl nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin e, and methods for preparing the synthetic nanoparticles. The disclosed synthetic ldl nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing ldl receptors after intra venous injection..
Arbor Therapeutics, Llc

Liposome composition and producing same

Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase..
Fujifilm Corporation

Use of cilastatin to reduce the nephrotoxicity of different compounds

Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts.
Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon

Novel 7-dehydrocholesterol derivatives and methods using same

The present invention provides, in certain aspects, novel 7-dehydrocholesterol (7dhc) derivatives that are useful in treating or preventing cancer, as well as in treating or preventing uncontrolled angiogenesis, in a subject. In certain embodiments of the present invention, the subject is a human.
Women & Infants Hospital Of Rhode Island

Compositions for the treatment of cataracts

In one embodiment, the present application discloses an aqueous ophthalmic composition for the treatment of eye diseases, lesions and injuries, comprising: a) one steroid, or a combination of at least two steroids selected from the group consisting of lanosterol, dihydrolanosterol, 4,4-dimethylcholesta-8(9),14,24-trien-3β-ol, 4,4-dimethylcholesta-8,24-dien-3β-ol, 4,4-dimethylcholesta-8-en-3β-ol, 4,4-dimethylcholesta-8(9),14-dien-3β-ol, 14-desmethyl lanosterol, lathosterol, Δ7,24-cholestadienol, cholesterol, cholesta-7-enol, cholesteryl ester, 7-dehydrocholesterol, desmosterol, 7-dehydrodesmosterol, zymosterol, 27-hydroxycholesterol, cholesta-7,24-dien-3-β-ol, cholesta-8(9)-en-3-β-ol, 5α-cholestan-3β-ol-6-one, 5-cholesten-3β,25-diol, 5-cholesten-3β,25-oso3h (5-cholesten-3β,25-sulfate), 5-cholesten-3β-oso3h,25-ol (5-cholesten-3β-sulfate,25-ol), 5-cholesten-3β,25-diol, disulfate, and their esters thereof, or a pharmaceutically acceptable salt thereof, in a concentration effective for the treatment and/or prophylaxis of the eye diseases, lesions and injuries; and b) a pharmaceutical excipient; and methods of treatment using such compositions.. .
Catacore, Inc.

Use of delta tocopherol for the treatment of lysosomal storage disorders

This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of δ tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders.
The United States Of America, As Represented By Secretary, Dept. Of Health & Human Services





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cholesterol for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cholesterol with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.2573

file did exist - 2580

2 - 1 - 52